TY - JOUR T1 - Case report study of the first five COVID-19 patients treated with remdesivir in France. AU - Dubert,Marie, AU - Visseaux,Benoit, AU - Isernia,Valentina, AU - Bouadma,Lila, AU - Deconinck,Laurène, AU - Patrier,Juliette, AU - Wicky,Paul-Henri, AU - Le Pluart,Diane, AU - Kramer,Laura, AU - Rioux,Christophe, AU - Le Hingrat,Quentin, AU - Houhou-Fidouh,Nadhira, AU - Yazdanpanah,Yazdan, AU - Ghosn,Jade, AU - Lescure,Francois-Xavier, Y1 - 2020/06/30/ PY - 2020/05/12/received PY - 2020/06/26/revised PY - 2020/06/26/accepted PY - 2020/7/4/pubmed PY - 2020/9/22/medline PY - 2020/7/4/entrez KW - Antiviral therapy KW - Case reports KW - Remdesivir KW - SARS-CoV-2 viral load KW - Viral pneumonia SP - 290 EP - 293 JF - International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases JO - Int J Infect Dis VL - 98 N2 - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been identified as the virus responsible for the coronavirus disease 2019 (COVID-19) outbreak worldwide. Data on treatment are scare and parallels have been made between SARS-CoV-2 and other coronaviruses. Remdesivir is a broad-spectrum antiviral with efficient in vitro activity against SARS-CoV-2. Evidence of clinical improvement in patients with severe COVID-19 treated with remdesivir is controversial. The aim of this study was to describe the clinical outcomes and virological monitoring of the first five COVID-19 patients admitted to the intensive care unit of Bichat-Claude Bernard University Hospital, Paris, France, for severe pneumonia related to SARS-CoV-2 and treated with remdesivir. Quantitative reverse transcription PCR was used to monitor SARS-CoV-2 in blood plasma and the lower and upper respiratory tract. Among the five patients treated, two needed mechanical ventilation and one needed high-flow cannula oxygen. A significant decrease in SARS-CoV-2 viral load in the upper respiratory tract was observed in most cases, but two patients died with active SARS-CoV-2 replication in the lower respiratory tract. Plasma samples were positive for SARS-CoV-2 in only one patient. Remdesivir was interrupted before the initialy planned duration in four patients, two because of alanine aminotransferase elevations (3 to 5 normal range) and two because of renal failure requiring renal replacement. This case series of five COVID-19 patients requiring intensive care unit treatment for respiratory distress and treated with remdesivir, highlights the complexity of remdesivir use in such critically ill patients. SN - 1878-3511 UR - https://www.unboundmedicine.com/medline/citation/32619764/Case_report_study_of_the_first_five_COVID_19_patients_treated_with_remdesivir_in_France_ DB - PRIME DP - Unbound Medicine ER -